Why the study?
The early cardiac modifications occurring in CKD that may trigger cardiac remodeling and dysfunction remain largely unexplored.
Does acute and transient CCL8 inhibition prevent cardiac remodeling and dysfunction in a mouse model of uremic cardiomyopathy?
Does acute and transient CCL8 inhibition prevent cardiac remodeling and dysfunction in a mouse model of uremic cardiomyopathy?
CCL8 is a key contributor to early cardiac inflammation in uremic cardiomyopathy, and its inhibition protects against subsequent cardiac remodeling and dysfunction in a mouse model.
Early cardiac transcriptional changes in CKD mice may inform targets; hypothesis-generating and requires human validation before practice change.
Uremic cardiomyopathy is a common complication in chronic kidney disease (CKD) patients, accounting for a high mortality rate. Several mechanisms have been proposed to link CKD and cardiac alterations; however, the early cardiac modifications that occur in CKD that may trigger cardiac remodeling and dysfunction remain largely unexplored. Here, in a mouse model of CKD induced by 5/6 nephrectomy, we first analyzed the early transcriptional and inflammatory changes that occur in the heart. Five days after 5/6 nephrectomy, RNA‐sequencing showed the upregulation of 54 genes in the cardiac tissue of CKD mice and the enrichment of biological processes related to immune system processes. Increased cardiac infiltration of T‐CD4 + lymphocytes, myeloid cells, and macrophages during early CKD was observed. Next, since CC chemokine ligand‐8 (CCL8) was one of the most upregulated genes in the heart of mice with early CKD, we investigated the effect of acute and transient CCL8 inhibition on uremic cardiomyopathy severity. An increase in CCL8 protein levels was confirmed in the heart of early CKD mice. CCL8 inhibition attenuated the early infiltration of T‐CD4 + lymphocytes and macrophages to the cardiac tissue, leading to a protection against chronic cardiac fibrotic remodeling, inflammation and cardiac dysfunction induced by CKD. Altogether, our data show the occurrence of transcriptional and inflammatory changes in the heart during the early phases of CKD and identify CCL8 as a key contributor to the early cardiac inflammatory state that triggers further cardiac remodeling and dysfunction in uremic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Amador‐Martínez et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: